GHRSGH Research PLC

Healthcare

$21.03+58% 1Y

$21.03

$12.4852 weeks$30.58

Price

+58%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 8% of companies

9/100

Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for GHRS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

Is the business good?not enough filed
Is it safe?Watch
Is the price fair?not enough filed
Is it growing?not enough filed
What is the market doing?Mixed

What they do

We are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. Our initial focus is on developing our novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression, or TRD. Our portfolio currently includes GH001, our proprietary inhalable mebufotenin product candidate and GH002, our proprietary intravenous mebufotenin product candidate.

In the company’s own words · 20-F filed Mar 5, 2026 · SEC EDGAR

P/En/a

Market value$1.74B

1 year+58%

5 years-9.8%